Switch to:
Also traded in: Austria, Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
ISRG's Cash-to-Debt is ranked higher than
97% of the 205 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. ISRG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ISRG' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.85  Med: No Debt Max: No Debt
Current: No Debt
12.85
No Debt
Equity-to-Asset 0.86
ISRG's Equity-to-Asset is ranked higher than
68% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ISRG: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
ISRG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7  Med: 0.87 Max: 0.9
Current: 0.86
0.7
0.9
Interest Coverage No Debt
ISRG's Interest Coverage is ranked higher than
96% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.92 vs. ISRG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ISRG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 7
Altman Z-Score: 36.40
Beneish M-Score: -2.56
WACC vs ROIC
10.18%
25.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 33.37
ISRG's Operating Margin % is ranked higher than
93% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.41 vs. ISRG: 33.37 )
Ranked among companies with meaningful Operating Margin % only.
ISRG' s Operating Margin % Range Over the Past 10 Years
Min: 25.56  Med: 35.7 Max: 40.3
Current: 33.37
25.56
40.3
Net Margin % 22.27
ISRG's Net Margin % is ranked higher than
87% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.18 vs. ISRG: 22.27 )
Ranked among companies with meaningful Net Margin % only.
ISRG' s Net Margin % Range Over the Past 10 Years
Min: 19.65  Med: 25.86 Max: 30.14
Current: 22.27
19.65
30.14
ROE % 14.51
ISRG's ROE % is ranked higher than
75% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.43 vs. ISRG: 14.51 )
Ranked among companies with meaningful ROE % only.
ISRG' s ROE % Range Over the Past 10 Years
Min: 12.17  Med: 17.77 Max: 21.36
Current: 14.51
12.17
21.36
ROA % 12.39
ISRG's ROA % is ranked higher than
83% of the 206 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. ISRG: 12.39 )
Ranked among companies with meaningful ROA % only.
ISRG' s ROA % Range Over the Past 10 Years
Min: 10.59  Med: 15.21 Max: 18.44
Current: 12.39
10.59
18.44
ROC (Joel Greenblatt) % 126.63
ISRG's ROC (Joel Greenblatt) % is ranked higher than
96% of the 204 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.63 vs. ISRG: 126.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ISRG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 117.99  Med: 186.03 Max: 245.9
Current: 126.63
117.99
245.9
3-Year Revenue Growth Rate 12.60
ISRG's 3-Year Revenue Growth Rate is ranked higher than
60% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. ISRG: 12.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ISRG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 17.2 Max: 57.1
Current: 12.6
0
57.1
3-Year EBITDA Growth Rate 21.90
ISRG's 3-Year EBITDA Growth Rate is ranked higher than
52% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. ISRG: 21.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ISRG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 29.4 Max: 90.9
Current: 21.9
0
90.9
3-Year EPS without NRI Growth Rate 15.30
ISRG's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.90 vs. ISRG: 15.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ISRG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26.8 Max: 76.8
Current: 15.3
0
76.8
» ISRG's 30-Y Financials

Financials (Next Earnings Date: 2019-01-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

ISRG Guru Trades in Q4 2017

Joel Greenblatt 12,960 sh (New)
John Hussman 10,000 sh (New)
Caxton Associates 3,612 sh (New)
Pioneer Investments 51,611 sh (New)
Lee Ainslie 27,020 sh (+63.73%)
Jim Simons 1,440,600 sh (+12.04%)
Steven Cohen Sold Out
Vanguard Health Care Fund 166,328 sh (-40.19%)
Robert Olstein 8,000 sh (-21.57%)
Ron Baron 27,720 sh (-4.57%)
Paul Tudor Jones 6,064 sh (-0.18%)
Eaton Vance Worldwide Health Sciences Fund 74,076 sh (-20.26%)
» More
Q1 2018

ISRG Guru Trades in Q1 2018

Ken Fisher 588 sh (New)
Steven Cohen 62,450 sh (New)
Mario Gabelli 1,168 sh (New)
Ron Baron 28,439 sh (+2.59%)
Lee Ainslie 30,530 sh (+12.99%)
Jim Simons 1,482,010 sh (+2.87%)
Pioneer Investments 67,535 sh (+30.85%)
Eaton Vance Worldwide Health Sciences Fund 74,076 sh (unchged)
Joel Greenblatt Sold Out
John Hussman Sold Out
Vanguard Health Care Fund 116,128 sh (-30.18%)
Robert Olstein 3,400 sh (-57.50%)
Paul Tudor Jones 4,805 sh (-20.76%)
Caxton Associates 3,133 sh (-13.26%)
» More
Q2 2018

ISRG Guru Trades in Q2 2018

Murray Stahl 438 sh (New)
Ken Fisher 907 sh (+54.25%)
Ron Baron 28,933 sh (+1.74%)
Steven Cohen 140,138 sh (+124.40%)
Paul Tudor Jones 8,685 sh (+80.75%)
Pioneer Investments 82,432 sh (+22.06%)
Mario Gabelli 1,315 sh (+12.59%)
Robert Olstein 3,400 sh (unchged)
Vanguard Health Care Fund 97,128 sh (-16.36%)
Lee Ainslie 22,010 sh (-27.91%)
Caxton Associates 1,885 sh (-39.83%)
Eaton Vance Worldwide Health Sciences Fund 63,142 sh (-14.76%)
Jim Simons 1,174,410 sh (-20.76%)
» More
Q3 2018

ISRG Guru Trades in Q3 2018

Spiros Segalas 334,203 sh (New)
Ken Fisher 1,221 sh (+34.62%)
Pioneer Investments 189,334 sh (+129.69%)
Murray Stahl 612 sh (+39.73%)
Ron Baron 34,045 sh (+17.67%)
Vanguard Health Care Fund Sold Out
Robert Olstein Sold Out
Lee Ainslie Sold Out
Eaton Vance Worldwide Health Sciences Fund 51,580 sh (-18.31%)
Mario Gabelli 1,305 sh (-0.76%)
Jim Simons 682,500 sh (-41.89%)
Steven Cohen 51,450 sh (-63.29%)
Caxton Associates 1,757 sh (-6.79%)
Paul Tudor Jones 919 sh (-89.42%)
» More
» Details

Insider Trades

Latest Guru Trades with ISRG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:BSX, NYSE:SYK, NYSE:EW, NYSE:ZBH, NAS:ALGN, LSE:SN., NAS:ABMD, NYSE:TFX, XSWX:SOON, NYSE:VAR, SZSE:300003, OCSE:WDH, XPAR:DIM, ASX:COH, LSE:CTEC, NZSE:FPH, NYSE:GMED, OCSE:AMBU B, NAS:IART, OCSE:GN » details
Traded in other countries:ISRG.Austria, IUI1.Germany, ISRG.Switzerland, 0R29.UK,
Headquarter Location:USA
Intuitive Surgical Inc designs, manufactures, markets da Vinci Surgical Systems, and related instruments. The da Vinci surgery, combines the benefits of minimally invasive surgery for patients with the ease of use, precision and dexterity of open surgery.

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed roughly 4,000 da Vinci systems in hospitals worldwide, with 2,600 installations in the United States and a growing number in emerging markets.

Guru Investment Theses on Intuitive Surgical Inc

Baron Opportunity Fund Comments on Intuitive Surgical - Feb 21, 2017

Intuitive Surgical (NASDAQ:ISRG) manufactures and markets the da Vinci Surgical System, a robotic surgical system consisting of a surgeon’s console, a patient-side cart, a high performance vision system and proprietary “wristed” instruments and surgical accessories. The da Vinci system seamlessly translates the surgeon’s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments inserted into the patient through small puncture incisions or ports. The da Vinci provides the surgeon with the intuitive control, range of motion, fine tissue manipulation capability and 3-D vision characteristics of open surgery, while simultaneously allowing the surgeon to work through the small ports of minimally-invasive surgery. Patients treated with the da Vinci system benefit from improved clinical results, smaller incisions, fewer complications, less blood loss, less nerve damage, reduced pain and faster recovery compared with open surgery. The company is targeting four million annual surgical procedures worldwide and, we believe, this target is likely to increase over time. In 2016, roughly 750,000 procedures were performed using Intuitive’s robotic systems, implying substantial runway for growth.



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical - Feb 13, 2017

After a multi-year hiatus, we re-initiated an investment in Intuitive Surgical, Inc. (NASDAQ:ISRG) Intuitive sells the da Vinci robotic surgical system, which enables surgeons to perform minimally-invasive surgery in a number of different procedure categories. Minimally-invasive surgery benefits patients because they generally experience less pain and faster recovery after the procedure. Intuitive has held an effective monopoly on robotic-assisted surgery for many years. We believe the company has durable competitive advantages consisting of patents, technology, regulatory approvals, a worldwide installed base of systems, large salesforce, and balance sheet with over $4 billion in net cash. Although Intuitive is expected to face competitors in the future, we believe it will be difficult for competitors to displace the company and the company will maintain its leadership position. In 2016, roughly 750,000 procedures were performed worldwide using Intuitive’s robotic systems, an increase of 15% year-over-year. Intuitive generates revenue from instruments/accessories every time a procedure is performed using its robotic system, which together with annual service fees provides recurring revenue. Management has defined its current addressable market as four million procedures, but we believe Intuitive will continue to expand its addressable market by entering new procedure areas. The company has an exciting pipeline of new products, including a single port system that will enable new procedures and a robotic catheter system that will enable lung tissue biopsies to be taken minimally invasively. In the fourth quarter, the stock pulled back despite a strong fundamental outlook because investors became concerned that the repeal of the Affordable Care Act would cause Intuitive’s hospital customers to cut capital spending, which would negatively impact Intuitive’s system sales. We saw this pull-back as short-sighted and bought the stock. We think Intuitive can grow revenue and earnings at attractive rates over the long term.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Intuitive Surgical Inc

Research Report Identifies Intuitive Surgical, Coherent, Jabil, Becton, Dickinson, IHS Markit, and Grand Canyon Education with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Rapid Micro Biosystems Announces New Vice President of Global Sales
Intuitive Announces New General Manager in Korea
Intuitive Announces New General Manager in Korea
Spiros Segalas Buys Ackman’s Chipotle in 3rd Quarter Fund manager establishes three new positions in latest portfolio report
Spiros Segalas (Trades, Portfolio), manager of the Harbor Capital Appreciation Fund, disclosed this week three new positions for the third quarter: Intuitive Surgical Inc. (NASDAQ:ISRG), Chipotle Mexican Grill Inc. (NYSE:CMG) and Tiffany & Co. (NYSE:TIF). Read more...
InTouch Health to Build an Internet of Medical Things Network for Intuitive
Intuitive Submits New Robotic-Assisted Platform to FDA for Obtaining Lung Biopsies
Intuitive Appoints Don Kania, Ph.D. to its Board of Directors
Weekly CFO Sells Highlight Insiders shed shares of Intuitive Surgical, CoStar, Westinghouse
According to GuruFocus insider data, the recent chief financial officer sells were Intuitive Surgical Inc. (NASDAQ:ISRG), CoStar Group Inc. (NASDAQ:CSGP) and Westinghouse Air Brake Technologies Corp. (NYSE:WAB). Read more...
Intuitive Surgical Receives FDA Clearance for First 60mm Stapler

Ratios

vs
industry
vs
history
PE Ratio 73.96
ISRG's PE Ratio is ranked lower than
99.99% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.70 vs. ISRG: 73.96 )
Ranked among companies with meaningful PE Ratio only.
ISRG' s PE Ratio Range Over the Past 10 Years
Min: 17.76  Med: 37.7 Max: 88.2
Current: 73.96
17.76
88.2
Forward PE Ratio 40.82
ISRG's Forward PE Ratio is ranked lower than
99.99% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.32 vs. ISRG: 40.82 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 73.96
ISRG's PE Ratio without NRI is ranked lower than
99.99% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. ISRG: 73.96 )
Ranked among companies with meaningful PE Ratio without NRI only.
ISRG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.76  Med: 37.7 Max: 88.2
Current: 73.96
17.76
88.2
Price-to-Owner-Earnings 71.60
ISRG's Price-to-Owner-Earnings is ranked lower than
93% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.92 vs. ISRG: 71.60 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ISRG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.18  Med: 41.09 Max: 91.2
Current: 71.6
18.18
91.2
PB Ratio 8.94
ISRG's PB Ratio is ranked lower than
99.99% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.45 vs. ISRG: 8.94 )
Ranked among companies with meaningful PB Ratio only.
ISRG' s PB Ratio Range Over the Past 10 Years
Min: 2.81  Med: 6.02 Max: 14.09
Current: 8.94
2.81
14.09
PS Ratio 16.34
ISRG's PS Ratio is ranked lower than
99.99% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.48 vs. ISRG: 16.34 )
Ranked among companies with meaningful PS Ratio only.
ISRG' s PS Ratio Range Over the Past 10 Years
Min: 4.15  Med: 9.79 Max: 21.18
Current: 16.34
4.15
21.18
Price-to-Free-Cash-Flow 58.08
ISRG's Price-to-Free-Cash-Flow is ranked lower than
99.99% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.61 vs. ISRG: 58.08 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ISRG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.4  Med: 31.21 Max: 76.47
Current: 58.08
18.4
76.47
Price-to-Operating-Cash-Flow 49.97
ISRG's Price-to-Operating-Cash-Flow is ranked lower than
99.99% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.15 vs. ISRG: 49.97 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ISRG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.33  Med: 26.85 Max: 63.06
Current: 49.97
11.33
63.06
EV-to-EBIT 44.62
ISRG's EV-to-EBIT is ranked lower than
99.99% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.93 vs. ISRG: 44.62 )
Ranked among companies with meaningful EV-to-EBIT only.
ISRG' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 26.5 Max: 60.5
Current: 44.62
10.2
60.5
EV-to-EBITDA 40.72
ISRG's EV-to-EBITDA is ranked lower than
99.99% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.49 vs. ISRG: 40.72 )
Ranked among companies with meaningful EV-to-EBITDA only.
ISRG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.4  Med: 24.1 Max: 56.9
Current: 40.72
9.4
56.9
EV-to-Revenue 14.88
ISRG's EV-to-Revenue is ranked lower than
99.99% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.57 vs. ISRG: 14.88 )
Ranked among companies with meaningful EV-to-Revenue only.
ISRG' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.6  Med: 9.1 Max: 20.8
Current: 14.88
3.6
20.8
PEG Ratio 13.02
ISRG's PEG Ratio is ranked lower than
100% of the 69 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. ISRG: 13.02 )
Ranked among companies with meaningful PEG Ratio only.
ISRG' s PEG Ratio Range Over the Past 10 Years
Min: 0.13  Med: 1.13 Max: 18.01
Current: 13.02
0.13
18.01
Shiller PE Ratio 94.71
ISRG's Shiller PE Ratio is ranked lower than
91% of the 54 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.97 vs. ISRG: 94.71 )
Ranked among companies with meaningful Shiller PE Ratio only.
ISRG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 44.24  Med: 77.4 Max: 282.22
Current: 94.71
44.24
282.22
Current Ratio 6.05
ISRG's Current Ratio is ranked lower than
51% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. ISRG: 6.05 )
Ranked among companies with meaningful Current Ratio only.
ISRG' s Current Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.64 Max: 7.43
Current: 6.05
2.07
7.43
Quick Ratio 5.52
ISRG's Quick Ratio is ranked higher than
55% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. ISRG: 5.52 )
Ranked among companies with meaningful Quick Ratio only.
ISRG' s Quick Ratio Range Over the Past 10 Years
Min: 1.72  Med: 4.34 Max: 7.07
Current: 5.52
1.72
7.07
Days Inventory 99.42
ISRG's Days Inventory is ranked higher than
60% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.35 vs. ISRG: 99.42 )
Ranked among companies with meaningful Days Inventory only.
ISRG' s Days Inventory Range Over the Past 10 Years
Min: 68.81  Med: 76.79 Max: 99.42
Current: 99.42
68.81
99.42
Days Sales Outstanding 59.50
ISRG's Days Sales Outstanding is ranked lower than
59% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.97 vs. ISRG: 59.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISRG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.57  Med: 61.12 Max: 71.25
Current: 59.5
48.57
71.25
Days Payable 33.01
ISRG's Days Payable is ranked lower than
99.99% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 54.66 vs. ISRG: 33.01 )
Ranked among companies with meaningful Days Payable only.
ISRG' s Days Payable Range Over the Past 10 Years
Min: 23.81  Med: 31.77 Max: 34.57
Current: 33.01
23.81
34.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.80
ISRG's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -5.00 vs. ISRG: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISRG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -115.5  Med: -1.5 Max: 2.4
Current: -0.8
-115.5
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 26.77
ISRG's Price-to-Net-Cash is ranked lower than
99.99% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.15 vs. ISRG: 26.77 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ISRG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.88  Med: 22.57 Max: 278
Current: 26.77
2.88
278
Price-to-Net-Current-Asset-Value 17.47
ISRG's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.83 vs. ISRG: 17.47 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ISRG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.21  Med: 12.75 Max: 28.53
Current: 17.47
2.21
28.53
Price-to-Tangible-Book 9.67
ISRG's Price-to-Tangible-Book is ranked lower than
99.99% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. ISRG: 9.67 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ISRG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.05  Med: 6.18 Max: 16.47
Current: 9.67
2.05
16.47
Price-to-Intrinsic-Value-Projected-FCF 3.60
ISRG's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. ISRG: 3.60 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ISRG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.45  Med: 2.77 Max: 19.2
Current: 3.6
1.45
19.2
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.38
ISRG's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
91% of the 23 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. ISRG: 3.38 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ISRG' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.19  Med: 1.47 Max: 3.03
Current: 3.38
1.19
3.03
Price-to-Median-PS-Value 1.67
ISRG's Price-to-Median-PS-Value is ranked lower than
99.99% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.13 vs. ISRG: 1.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ISRG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 0.98 Max: 2.15
Current: 1.67
0.31
2.15
Price-to-Peter-Lynch-Fair-Value 5.69
ISRG's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. ISRG: 5.69 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ISRG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.42 Max: 10.12
Current: 5.69
0.63
10.12
Price-to-Graham-Number 5.64
ISRG's Price-to-Graham-Number is ranked lower than
99.99% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. ISRG: 5.64 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ISRG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.8  Med: 3.61 Max: 8.01
Current: 5.64
1.8
8.01
Earnings Yield (Greenblatt) % 2.24
ISRG's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 207 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. ISRG: 2.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ISRG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.7  Med: 3.8 Max: 9.8
Current: 2.24
1.7
9.8
Forward Rate of Return (Yacktman) % 14.36
ISRG's Forward Rate of Return (Yacktman) % is ranked lower than
57% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.66 vs. ISRG: 14.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ISRG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.4  Med: 21.3 Max: 25.4
Current: 14.36
1.4
25.4

More Statistics

Revenue (TTM) (Mil) $3,560.40
EPS (TTM) $ 6.65
Beta1.20
Volatility26.73%
52-Week Range $359.75 - 581.12
Shares Outstanding (Mil)114.20

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 3,709 4,371 5,028
EBIT (Mil $) 1,548 1,735 1,985
EBITDA (Mil $) 1,654 1,856 2,124
EPS ($) 9.92 12.24 14.00
EPS without NRI ($) 9.92 12.24 14.00
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}